Abstract Details

Title The Use of OnabotulinumtoxinA for the Treatment of Chronic Migraine During Pregnancy: An American Headache Society Survey Study

Topic Headache

Presentation(s) P7 - Poster Session 7 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-003

Objective

To generate a statistical snapshot of physicians’ perspectives and treatment practices regarding use of onabotulinumtoxinA (onabotA) for treating chronic migraine during pregnancy.

Background OnabotA is an FDA-approved neurotoxin for treating chronic migraine. However, limited data exists regarding the safety of onabotA in pregnancy. The therapeutic options for migraine during pregnancy are currently limited and few studies have been conducted to explore physicians’ practices regarding the use of botulinum toxin in pregnancy.

Design/Methods A 15-question survey exploring physicians’ clinical practices using botulinum toxin injections for chronic migraine was distributed online to members of the American Headache Society. The final 4 questions pertained to use in pregnancy. Descriptive analysis was performed.

Results A total of 168 respondents (162 from the United States and 6 from Canada) completed the survey (response rate 10.1% [168/1665]). Of the respondents, 96 (58%) reported not using OnabotA during pregnancy; 97 (59%) reported continuing use of onabotA while a patient is actively trying to become pregnant; 94 (57%) reported discontinuation of onabotA treatment when a patient become pregnant; 117 (71%) reported that they have or would consider resuming onabotA treatment during pregnancy should a patient experience refractory headache after discontinuation of the treatment.

Conclusions Of the providers sampled, a slight majority avoided use of onabotA during pregnancy, however would use or consider using onabotA should the patient develop refractory headache after discontinuation of onabotA due to pregnancy. Additionally, the majority of providers did not discontinue onabotA while a patient is actively trying to become pregnant.

Authors/Disclosures
Justin Nofar, MD PRESENTER	Dr. Nofar has nothing to disclose.
Kendra K. Davis (Henry Ford Hospital)	Ms. Davis has nothing to disclose.
Paul G. Mathew, MD, DNBPAS, FAHS, FACSM, FAAN (Harvard Medical School/Mass General Brigham/Atrius Health)	Dr. Mathew has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie/Allergan. Dr. Mathew has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Mathew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Mathew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven/Pfizer. Dr. Mathew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Mathew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel. Dr. Mathew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher Smith. Dr. Mathew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Mathew has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie.
Ashhar Ali, DO, FAAN (Henry Ford Health)	Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Ebsco.

��ɫ��

��ɫ��